Abstract
This chapter reviews the known toxicity profile of anti-retroviral drugs based on information from such drug use in human immunodeficiency virus (HIV) infected patients, and then reviews the limited toxicity data reported by several small studies of health care workers who have taken HIV post-exposure prophylaxis (PEP). Suggestions for an approach to monitoring and managing PEP toxicity are then discussed. Managing HIV exposures and HIV PEP toxicity requires clinical training and experience. Because experience with the side-effects of the available anti-retroviral agents is limited and reports of toxicity continue to emerge, it is important that health care providers who manage HIV exposures stay up to date with the latest information on HIV PEP and make use of expert consultation as needed.
| Original language | English |
|---|---|
| Pages (from-to) | 349-363 |
| Number of pages | 15 |
| Journal | Bailliere's Clinical Infectious Diseases |
| Volume | 5 |
| Issue number | 3 |
| Publication status | Published - 1998 |
Fingerprint
Keywords
- Anti-retroviral drug side-effects
- Anti-retroviral drug toxicity
- Human immunodeficiency virus post-exposure prophylaxis
ASJC Scopus subject areas
- Immunology
- Microbiology (medical)
Cite this
Toxicity of post-exposure prophylaxis for human immunodeficiency virus. / Wang, S. A.; Puro, V.
In: Bailliere's Clinical Infectious Diseases, Vol. 5, No. 3, 1998, p. 349-363.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Toxicity of post-exposure prophylaxis for human immunodeficiency virus
AU - Wang, S. A.
AU - Puro, V.
PY - 1998
Y1 - 1998
N2 - This chapter reviews the known toxicity profile of anti-retroviral drugs based on information from such drug use in human immunodeficiency virus (HIV) infected patients, and then reviews the limited toxicity data reported by several small studies of health care workers who have taken HIV post-exposure prophylaxis (PEP). Suggestions for an approach to monitoring and managing PEP toxicity are then discussed. Managing HIV exposures and HIV PEP toxicity requires clinical training and experience. Because experience with the side-effects of the available anti-retroviral agents is limited and reports of toxicity continue to emerge, it is important that health care providers who manage HIV exposures stay up to date with the latest information on HIV PEP and make use of expert consultation as needed.
AB - This chapter reviews the known toxicity profile of anti-retroviral drugs based on information from such drug use in human immunodeficiency virus (HIV) infected patients, and then reviews the limited toxicity data reported by several small studies of health care workers who have taken HIV post-exposure prophylaxis (PEP). Suggestions for an approach to monitoring and managing PEP toxicity are then discussed. Managing HIV exposures and HIV PEP toxicity requires clinical training and experience. Because experience with the side-effects of the available anti-retroviral agents is limited and reports of toxicity continue to emerge, it is important that health care providers who manage HIV exposures stay up to date with the latest information on HIV PEP and make use of expert consultation as needed.
KW - Anti-retroviral drug side-effects
KW - Anti-retroviral drug toxicity
KW - Human immunodeficiency virus post-exposure prophylaxis
UR - http://www.scopus.com/inward/record.url?scp=0032228682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032228682&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0032228682
VL - 5
SP - 349
EP - 363
JO - Bailliere's Clinical Infectious Diseases
JF - Bailliere's Clinical Infectious Diseases
SN - 1071-6564
IS - 3
ER -